Clario, a provider of endpoint data solutions, has partnered with PathAI, an AI-powered digital pathology solutions company, to improve gastrointestinal (GI) clinical trials.
The partnership aims to offer a single-vendor solution that combines Clario's advanced imaging solutions like endoscopy with PathAI's AI-powered histopathology services. This integrated approach will streamline endoscopic and histopathology end points, improving efficiency in global GI studies.
The collaboration will benefit CROs, sponsors, and investigational sites by providing simplified workflows, improved training, reporting, and document management. It is expected to enhance diagnostic accuracy, boost efficiency, and enable reliable turnaround times in GI clinical trials, particularly for inflammatory bowel disease (IBD) and ulcerative colitis (UC) studies.
Analyst QuickTake: This marks the second partnership Clario has secured in 2024. In August , the company partnered with Mobilise-D consortium to integrate Mobilise-D's validated algorithms into Clario's Opal wearable sensor system, enabling real-world mobility assessments for patients. Partnerships such as those secured with PathAI and with Mobilise-D help Clrio to expand both the platform’s functionality along with its market presence in the clinical trial space.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.